NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
Agreement Announcement: August 19, 2021
Transaction Details:Under the terms of the merger, Inovalon stockholders will receive $41.00 per share in cash for each share of Class A Common Stock or Class B Common Stock.
For details on the INOV investigation or if you want more information about your rights as a shareholder, complete this brief submission form:
Rafael Holdings, Inc. (NYSE:RFL)
Agreement Announcement: August 16, 2021
Transaction Details:Under the terms of the merger, Rafael Pharmaceuticals, Inc. shareholders will own approximately 48% of the combined company.
For details on the RFL investigation or if you want more information about your rights as a shareholder, complete this brief submission form:
WHY LEVI & KORSINSKY: Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the U.S. and internationally. Founded by Joseph Levi and Eduard Korsinsky over 20 years ago, Levi & Korsinsky has achieved remarkable results, fighting for shareholders who have been wronged by corporations and winning cases worth hundreds of millions of dollars. Levi & Korsinsky was ranked in Institutional Shareholder Services' ("ISS") SCAS Top 50 Report for 7 years in a row as a top securities litigation firm in the United States. The SCAS Top 50 Report identifies the top plaintiffs' securities law firms in the country, and year after year, ISS has recognized Levi & Korsinsky as a leading firm in the area of securities class action litigation.
For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP